180 related articles for article (PubMed ID: 36042046)
1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
Valcarcel S; Gallego J; Jimenez-Fonseca P; Diez M; de Castro EM; Hernandez R; Arrazubi V; Custodio A; Cano JM; Montes AF; Macias I; Visa L; Calvo A; Tocino RV; Lago NM; Limón ML; Granja M; Gil M; Pimentel P; Macia-Rivas L; Pérez CH; Mangas M; Carnicero AM; Cerdà P; Gonzalez LG; Navalon FG; Rambla MDM; Richard MM; Carmona-Bayonas A
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4077-4089. PubMed ID: 36042046
[TBL] [Abstract][Full Text] [Related]
2. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
3. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Kim BJ; Jee HJ; Rha SY; Han HS; Ryu MH; Park SH; Kim JG; Bae WK; Lee KW; Oh DY; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Gastric Cancer; 2022 May; 25(3):609-618. PubMed ID: 35015188
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study.
Abdel-Rahman O; Mulder K; Easaw J
Am J Clin Oncol; 2021 Apr; 44(4):158-161. PubMed ID: 33625121
[TBL] [Abstract][Full Text] [Related]
9. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca P; Foy V; Raby S; Carmona-Bayonas A; Macía-Rivas L; Arrazubi V; Cacho Lavin D; Hernandez San Gil R; Custodio A; Cano JM; Fernández Montes A; Mirallas O; Macias Declara I; Vidal Tocino R; Visa L; Limón ML; Pimentel P; Martínez Lago N; Sauri T; Martín Richard M; Mangas M; Gil Raga M; Calvo A; Reguera P; Granja M; Martín Carnicero A; Hernández Pérez C; Cerdá P; Gomez Gonzalez L; Garcia Navalon F; Pacheco Barcia V; Gutierrez Abad D; Ruiz Martín M; Weaver J; Mansoor W; Gallego J
Ther Adv Med Oncol; 2023; 15():17588359231157641. PubMed ID: 36895850
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Xiao L; Amlashi FG; Elimova E; Blum Murphy MA; Sanders E; Shanbhag N; Thomas I; Ajani JA
Oncology; 2019; 96(5):252-258. PubMed ID: 30893708
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S; Thuss-Patience P; Pauligk C; Gökkurt E; Ettrich T; Lordick F; Stahl M; Reichardt P; Sökler M; Pink D; Probst S; Hinke A; Goetze TO; Al-Batran SE
Eur J Cancer; 2022 Apr; 165():48-57. PubMed ID: 35202974
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Lorenzen S; Schwarz A; Pauligk C; Goekkurt E; Stocker G; Knorrenschild JR; Illerhaus G; Dechow T; Moehler M; Moulin JC; Pink D; Stahl M; Schaaf M; Goetze TO; Al-Batran SE
BMC Cancer; 2023 Jun; 23(1):561. PubMed ID: 37337155
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
16. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Plazas JG; Arias-Martinez A; Lecumberri A; Martínez de Castro E; Custodio A; Cano JM; Hernandez R; Montes AF; Macias I; Pieras-Lopez A; Diez M; Visa L; Tocino RV; Lago NM; Limón ML; Gil M; Pimentel P; Mangas M; Granja M; Carnicero AM; Pérez CH; Gonzalez LG; Jimenez-Fonseca P; Carmona-Bayonas A
ESMO Open; 2022 Jun; 7(3):100514. PubMed ID: 35714478
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P; Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Lecumberri A; Cacho Lavin D; Losantos García I; Fernández Montes A; Cano JM; Limón ML; Hernández San Gil R; Diez M; Vidal Tocino R; Macías Declara I; Visa L; Pimentel Cáceres P; Gil Raga M; Martínez Moreno E; Sauri T; Martín Richard M; Granja M; Cerdà P; Gómez González L; Mérida-García A; Ruiz Martín M; Gallego J;
Gastric Cancer; 2024 Jan; 27(1):131-145. PubMed ID: 37964032
[TBL] [Abstract][Full Text] [Related]
19. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
20. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
Al-Batran SE; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov ON; Kim TY; Cunningham D; Rougier P; Muro K; Liepa AM; Chandrawansa K; Emig M; Ohtsu A; Wilke H
Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
